Corcept Therapeutics, Inc. (CORT)
111.62
-1.18
(-1.05%)
USD |
NASDAQ |
Sep 04, 16:00
111.62
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Research and Development Expense (Quarterly) : 53.89M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.89M |
| March 31, 2026 | 66.26M |
| December 31, 2025 | 64.86M |
| September 30, 2025 | 68.85M |
| June 30, 2025 | 60.47M |
| March 31, 2025 | 60.74M |
| December 31, 2024 | 70.30M |
| September 30, 2024 | 59.34M |
| June 30, 2024 | 58.74M |
| March 31, 2024 | 58.50M |
| December 31, 2023 | 54.71M |
| September 30, 2023 | 45.52M |
| June 30, 2023 | 43.28M |
| March 31, 2023 | 40.85M |
| December 31, 2022 | 36.75M |
| September 30, 2022 | 33.29M |
| June 30, 2022 | 32.82M |
| March 31, 2022 | 28.12M |
| December 31, 2021 | 28.52M |
| September 30, 2021 | 28.09M |
| June 30, 2021 | 28.23M |
| March 31, 2021 | 29.02M |
| December 31, 2020 | 28.28M |
| September 30, 2020 | 33.87M |
| June 30, 2020 | 26.50M |
| Date | Value |
|---|---|
| March 31, 2020 | 26.12M |
| December 31, 2019 | 24.31M |
| September 30, 2019 | 22.80M |
| June 30, 2019 | 21.66M |
| March 31, 2019 | 20.24M |
| December 31, 2018 | 18.79M |
| September 30, 2018 | 18.86M |
| June 30, 2018 | 20.54M |
| March 31, 2018 | 17.05M |
| December 31, 2017 | 13.63M |
| September 30, 2017 | 11.69M |
| June 30, 2017 | 7.876M |
| March 31, 2017 | 7.176M |
| December 31, 2016 | 6.484M |
| September 30, 2016 | 7.054M |
| June 30, 2016 | 5.672M |
| March 31, 2016 | 4.634M |
| December 31, 2015 | 4.089M |
| September 30, 2015 | 3.612M |
| June 30, 2015 | 3.341M |
| March 31, 2015 | 4.377M |
| December 31, 2014 | 3.789M |
| September 30, 2014 | 3.047M |
| June 30, 2014 | 4.252M |
| March 31, 2014 | 7.285M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Liquidia Corp. | 16.88M |
| Eli Lilly & Co. | 3.819B |
| Indivior Pharmaceuticals, Inc. | 7.00M |
| Crinetics Pharmaceuticals, Inc. | 99.38M |
| Merck & Co., Inc. | 9.229B |